Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Berlin - Delayed Quote EUR

Xencor Inc (XE9.BE)

Compare
8.35
+0.30
+(3.73%)
At close: 8:00:19 AM GMT+2
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
110,493
110,493
174,615
164,579
275,111
Operating Expense
288,901
288,901
306,977
247,052
231,344
Operating Income
-178,408
-178,408
-132,362
-82,473
43,767
Net Non Operating Interest Income Expense
-4,713
-4,713
13,154
4,817
849
Other Income Expense
-51,802
-51,802
-426
23,148
38,015
Pretax Income
-234,923
-234,923
-119,634
-54,508
82,631
Tax Provision
1,617
1,617
13,662
673
--
Net Income Common Stockholders
-232,618
-232,618
-133,133
-55,181
82,631
Diluted NI Available to Com Stockholders
-232,618
-232,618
-133,133
-55,181
82,631
Basic EPS
-3.58
--
-2.20
-0.93
1.42
Diluted EPS
-3.58
--
-2.20
-0.93
1.37
Basic Average Shares
65,041.27
--
60,503.28
59,652.46
58,379.64
Diluted Average Shares
65,041.27
--
60,503.28
59,652.46
60,495.46
Total Operating Income as Reported
-178,408
-178,408
-132,362
-82,473
43,767
Total Expenses
288,901
288,901
306,977
247,052
231,344
Net Income from Continuing & Discontinued Operation
-232,618
-232,618
-133,133
-55,181
82,631
Normalized Income
-191,654.92
-191,654.92
-132,820.95
-73,584.84
43,342
Interest Income
31,930
31,930
19,331
4,830
862
Interest Expense
36,643
36,643
6,177
13
13
Net Interest Income
-4,713
-4,713
13,154
4,817
849
EBIT
-198,280
-198,280
-113,457
-54,495
82,644
EBITDA
-186,173
-186,173
-101,959
-45,696
90,135
Reconciled Depreciation
12,107
12,107
11,498
8,799
7,491
Net Income from Continuing Operation Net Minority Interest
-232,618
-232,618
-133,133
-55,181
82,631
Total Unusual Items Excluding Goodwill
-51,852
-51,852
-395
23,296
39,289
Total Unusual Items
-51,852
-51,852
-395
23,296
39,289
Normalized EBITDA
-134,321
-134,321
-101,564
-68,992
50,846
Tax Rate for Calcs
0
0
0
0
--
Tax Effect of Unusual Items
-10,888.92
-10,888.92
-82.95
4,892.16
--
12/31/2021 - 12/10/2013

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

LGDN.F Ligand Pharmaceuticals Incorporated
89.50
-2.19%
 
S09.F Sutro Biopharma, Inc.
0.4700
-4.39%
 
XOMA XOMA Royalty Corporation
21.18
+3.17%
 
PLX Protalix BioTherapeutics, Inc.
2.6100
+0.38%
 
CHRS Coherus BioSciences, Inc.
1.1200
+10.89%
 
HALO Halozyme Therapeutics, Inc.
58.79
-0.05%
 
BBIO BridgeBio Pharma, Inc.
33.87
+0.06%